ѻý

<ѻý class="page-title">Meeting Coverage

CTOS

<ѻý class="page-description">Connective Tissue Oncology Society
Chemo-ICI Combo Promising in Soft Tissue Sarcoma

PFS rate of 69% at 12 weeks in liposarcoma patients with eribulin and pembrolizumab

CTOS over a microscopy of myxoid liposarcoma.
<ѻý class="section_title">Latest CTOS Meeting Coverage
Active Surveillance Still the Best Bet in Desmoid-Type Fibromatosis

GRAFITI trial show's less than a third of watched patients eventually need active treatment

November 13, 2021
T-Cell Therapy Shows Promise in Rare Sarcomas

Afami-cel induced durable responses in synovial sarcoma and myxoid/round cell liposarcoma

November 12, 2021
High COVID Complication Rates in Sarcoma Patients

Half of patients in registry-based study were hospitalized

November 12, 2021
Ripretinib Continues to Demonstrate Benefit in Advanced GIST

Updated analysis shows stable PFS, improved OS

November 11, 2021
Potential New Option in Aggressive, Ultra Rare Sarcoma

Highly durable responses with nab-sirolimus in malignant PEComa

November 21, 2020
Cellular Therapies Promising in Advanced Synovial Sarcoma

Two different strategies yield impressive results in patients with recurrent or metastatic disease

November 20, 2020
Tiny Lung Micronodules in Bone Sarcoma Not Even a Tiny Problem?

Five-year survival no worse in patients with micronodules under 5 mm

November 20, 2020